Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DVAX
stocks logo

DVAX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
80.26M
+11.43%
0.015
-70%
84.68M
+24.22%
0.125
-116.23%
105.51M
+10.55%
0.215
+53.57%
Estimates Revision
The market is revising Upward the revenue expectations for Dynavax Technologies Corporation (DVAX) for FY2025, with the revenue forecasts being adjusted by 1.13% over the past three months. During the same period, the stock price has changed by 8.95%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.13%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.8%
In Past 3 Month
Stock Price
Go Up
up Image
+8.95%
In Past 3 Month
Wall Street analysts forecast DVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVAX is 21.00 USD with a low forecast of 11.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast DVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVAX is 21.00 USD with a low forecast of 11.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 10.960
sliders
Low
11.00
Averages
21.00
High
32.00
Current: 10.960
sliders
Low
11.00
Averages
21.00
High
32.00
Citizens JMP
Roy Buchanan
Outperform
maintain
$31 -> $32
2025-08-08
Reason
Citizens JMP
Roy Buchanan
Price Target
$31 -> $32
2025-08-08
maintain
Outperform
Reason
Citizens JMP analyst Roy Buchanan raised the firm's price target on Dynavax to $32 from $31 and keeps an Outperform rating on the shares. Dynavax continues to focus on priorities in HEPLISAV-B, business development, and the pipeline with the board battle behind it, the analyst tells investors in a research note.
Goldman Sachs
Paul Choi
Strong Sell
Maintains
$12 → $10
2025-04-17
Reason
Goldman Sachs
Paul Choi
Price Target
$12 → $10
2025-04-17
Maintains
Strong Sell
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$31
2025-02-21
Reason
HC Wainwright & Co.
Edward White
Price Target
$31
2025-02-21
Reiterates
Strong Buy
Reason
Citizens Capital Markets
Jason Butler
Buy
Maintains
$29 → $33
2025-02-21
Reason
Citizens Capital Markets
Jason Butler
Price Target
$29 → $33
2025-02-21
Maintains
Buy
Reason
Citizens JMP raised the firm's price target on Dynavax to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported fiscal 2024 results in line with January's preannouncement, and management remains optimistic on the potential for bringing in value-add, late-stage assets in the infectious disease space as the best way to maximize the value of its hepatitis B vaccine, HEPLISAV-B, the analyst tells investors in a research note. Management also continues to seek out assets in the infectious disease space, and believes there are viable assets, the firm notes.
Goldman Sachs
Paul Choi
Hold
to
Strong Sell
Downgrades
$15 → $12
2025-02-11
Reason
Goldman Sachs
Paul Choi
Price Target
$15 → $12
2025-02-11
Downgrades
Hold
to
Strong Sell
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Maintains
$29 → $31
2025-01-14
Reason
HC Wainwright & Co.
Edward White
Price Target
$29 → $31
2025-01-14
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Dynavax Technologies Corp (DVAX.O) is 19.06, compared to its 5-year average forward P/E of -3.99. For a more detailed relative valuation and DCF analysis to assess Dynavax Technologies Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.99
Current PE
19.06
Overvalued PE
118.55
Undervalued PE
-126.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
64.32
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
261.70
Undervalued EV/EBITDA
-133.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.25
Current PS
0.00
Overvalued PS
5.95
Undervalued PS
2.56
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 2687.45% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 122.6% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 2687.45% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

DVAX News & Events

Events Timeline

(ET)
2025-11-05
16:06:35
Dynavax Announces Q3 Earnings Per Share of 21 Cents, Up from 12 Cents Last Year
select
2025-11-05
16:03:09
Dynavax Secures Licensing Deal for Vaxart's Oral COVID-19 Vaccine Initiative
select
2025-10-21 (ET)
2025-10-21
16:04:52
Dynavax announces findings from Phase 1/2 clinical trial of Z-1018
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-02MarketWatch
Vaccine Shares Drop After FDA Official Connects COVID Vaccines to Heart Issues in Young Men

  • Market Reaction: Shares of Moderna and BioNTech fell on Monday morning following a memo from a FDA official linking COVID-19 mRNA vaccines to myocarditis deaths in 10 children.

  • Public Concern: The potential link between mRNA vaccines and myocarditis, especially in teenage boys and young men, has fueled arguments against vaccinating children with these vaccines.

[object Object]
Preview
2.0
12-01NASDAQ.COM
DVAX Falls Below Important Moving Average Threshold
  • 52 Week Range: DVAX's stock has a 52-week low of $9.20 and a high of $14.63, with the last trade recorded at $10.71.
  • Market Analysis: The article mentions other stocks that have recently fallen below their 200-day moving average.
  • Author's Perspective: The views expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.
  • Stock Performance Insight: The information provided offers insight into DVAX's stock performance within the context of its recent trading activity.
[object Object]
Preview
8.0
11-24NASDAQ.COM
Options Trading for Dynavax Technologies (DVAX) in the First Week of July 2026

  • Put Contract Overview: The $11.00 put contract for DVAX has a bid of 60 cents, allowing investors to buy shares at $11.00 while effectively lowering their cost basis to $10.40, presenting a potential 2% discount compared to the current price of $11.27.

  • Expiration Odds and Returns: There is a 62% chance that the put contract may expire worthless, which would yield a 5.45% return on the cash commitment, or 8.47% annualized, referred to as YieldBoost.

  • Call Contract Strategy: The $12.00 call contract has a bid of 55 cents, and if shares are purchased at $11.27 and the call is sold, it could result in an 11.36% total return if the stock is called away by July 2026.

  • Covered Call Expiration Odds: The call contract has a 49% chance of expiring worthless, allowing the investor to retain both the shares and the premium, which would provide a 4.88% additional return, or 7.58% annualized, also termed YieldBoost.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Dynavax Technologies Corp (DVAX) stock price today?

The current price of DVAX is 10.96 USD — it has decreased -0.09 % in the last trading day.

arrow icon

What is Dynavax Technologies Corp (DVAX)'s business?

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

arrow icon

What is the price predicton of DVAX Stock?

Wall Street analysts forecast DVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVAX is 21.00 USD with a low forecast of 11.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Dynavax Technologies Corp (DVAX)'s revenue for the last quarter?

Dynavax Technologies Corp revenue for the last quarter amounts to 94.88M USD, increased 17.67 % YoY.

arrow icon

What is Dynavax Technologies Corp (DVAX)'s earnings per share (EPS) for the last quarter?

Dynavax Technologies Corp. EPS for the last quarter amounts to 0.20 USD, increased 81.82 % YoY.

arrow icon

What changes have occurred in the market's expectations for Dynavax Technologies Corp (DVAX)'s fundamentals?

The market is revising Upward the revenue expectations for Dynavax Technologies Corporation (DVAX) for FY2025, with the revenue forecasts being adjusted by 1.13% over the past three months. During the same period, the stock price has changed by 8.95%.
arrow icon

How many employees does Dynavax Technologies Corp (DVAX). have?

Dynavax Technologies Corp (DVAX) has 405 emplpoyees as of December 05 2025.

arrow icon

What is Dynavax Technologies Corp (DVAX) market cap?

Today DVAX has the market capitalization of 1.29B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free